Practice

The Top 5 Biosimilars Articles for the Week of February 11

February 15th 2019

The Center for Biosimilars® recaps the top news for the week of February 11, 2019.

CT-P13 in IBD Is Safe and Effective in the Long Term, Research Shows

February 14th 2019

By Kelly Davio

Evidence to support treating inflammatory bowel disease (IBD), a category that includes Crohn disease and ulcerative colitis, with biosimilar infliximab continues to develop, and several new studies highlight the safety and efficacy of long-term treatment with CT-P13 (Inflectra, Remsima).

New Research Highlights the Role of Biosimilar Etanercept in Treating Ankylosing Spondylitis

February 13th 2019

By Kelly Davio

While the United States continues to await the launch of the first FDA-approved biosimilar etanercept (Erelzi), in other parts of the world biosimilars of the reference etanercept (Enbrel) are being widely used in clinical practice, and recent research reports on the role that biosimilar etanercept plays in the treatment of ankylosing spondylitis (AS).

Infliximab Saves on Short-Term Costs in ASUC, and Biosimilars Could Help

February 12th 2019

By Kelly Davio

Acute severe ulcerative colitis (ASUC) can occur in up to 25% of patients with UC. Salvage therapy with infliximab or cyclosporine is standard first-line therapy for patients who do not respond adequately to intravenous corticosteroids, but questions have arisen about the cost-effectiveness of this approach versus early colectomy. A recent study, conducted in a tertiary hospital network in Australia, sought to compare healthcare utilization and costs between patients with ASUC who had early colectomy and those who were treated with infliximab.

No Safety Risks Found in a Switch From Reference Rituximab to GP2013

February 8th 2019

By Kelly Davio

GP2013, a biosimilar rituximab developed by Sandoz and licensed in the European Union under the brand names Rixathon and Riximyo, is used to treat both malignant and inflammatory diseases. A recently published paper, appearing in Arthritis Care and Research, says that researchers detected no safety risks when switching patients with rheumatoid arthritis from reference rituximab (Rituxan) to the biosimilar.

CT-P10 Shows Long-Term Similarity to EU and US Reference Rituximab in RA

February 7th 2019

By Kelly Davio

New research, published in BioDrugs, underscores the long-term efficacy and safety of treating rheumatoid arthritis (RA) with biosimilar rituximab, CT-P10.

Paper Questions Utility of DANBIO Results for Switching to Biosimilar Etanercept

February 4th 2019

By The Center for Biosimilars Staff

In a newly published correspondence, Italian rheumatology providers called into question whether recently published results from the DANBIO registry can be used to guide non-medical switching from reference etanercept (Enbrel) to biosimilar SB4 (Benpali) in patients with inflammatory diseases.

Biosimilar Education Roundup: January 2019

January 31st 2019

By Kelly Davio

While the body of reassuring data on the safety and efficacy of biosimilars continues to grow, worrisome information about stakeholders’ levels of awareness of these products is also coming to light, and January 2019 saw the publication of a spate of studies showing low levels of patient and provider education on biosimilars.

More Research Finds Low Awareness of Biosimilars Among Oncology Providers

January 29th 2019

By Kelly Davio

While a majority of survey respondents said that they were at least somewhat familiar with current developments in oncology biosimilars, analyses of open-ended definitions found that only 1 participant could fully define a biosimilar, according to researchers.

NHS Provides Update on Biosimilar Adalimumab With a Focus on ISRs

January 29th 2019

By Kelly Davio

Biosimilar adalimumab is making its way to patients, some of whom have expressed concerns about the presence of citrate in some of the available biosimilars.